Vascular BioSciences (VBS) is a biopharmaceutical and medical device company headquartered in Durham, NC with facilites in California, Focused on developing solutions for difficult-to-treat cardiovascular and inflammatory diseases the leading cause of serious illness and death in industrialized countries, the firm offers interventional devices and personalized molecular diagnostics. makes interventional catheters to obtain pulmonary endoarterial biopsies, provides molecular diagnostic services, and through its majority-owned subsidiary, VBS Pharmaceuticals, advances targeted therapies to enhance and prolong human life. The company's lead therapeutic candidate, CARSKNKDC (CAR) peptide: a targeted therapy. CAR preferentially homes to, and penetrates, diseased tissue while selectively augmenting the efficacy of therapies and accelerating wound healing. CAR can selectively enhance gene therapy, boost drug effectiveness, and reduce systemic side effects by enhancing the efficacy of co-administered therapeutics. The firm's efforts organize around finding better solutions for treating vascular-based diseases. THis focus has resulted in a method of endoarterial biopsy sampling that does not require invasive surgery. When endoarterial biopsies are combined with their molecular diagnostic techniques, it is suggested that this would enable identification of the molecular signatures underlying each patients vascular disease allowing selection of therapeutics precisely target each patients individual disease pathways.
